PCP prophylaxis was often individualized and based on (combinations of) CD4+ T cell counts, duration of immunosuppressive therapy and combinations of immunosuppressants, particularly the combination of a DMARD with systemic glucocorticoids. The gene discussed is CD4; the disease is pneumocystosis.